For metastatic colorectal and lung cancer patients, where treatment with anti-EGFR monoclonal antibodies is only effective in patients whose tumours are RAS wild type, sequencing 3 exons of KRAS and 3 exons of NRAS is required, and this will possibly also be the case for other tumour types shortly. The gene discussed is KRAS; the disease is lung carcinoma.